Spark Therapeutics, Inc. Common Stock
ONCE
ONCE was delisted on the 16th of December, 2019.
119 hedge funds and large institutions have $1.38B invested in Spark Therapeutics, Inc. Common Stock in 2016 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 53 increasing their positions, 29 reducing their positions, and 18 closing their positions.
111% more call options, than puts
Call options by funds: $2.17M | Put options by funds: $1.03M
83% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 29
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 18
2% less funds holding
Funds holding: 121 → 119 (-2)
10% less capital invested
Capital invested by funds: $1.54B → $1.38B (-$160M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$54.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$21.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7.24M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$6.03M |
| 5 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$27.8M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$14.1M |
| 3 |
VOYA Investment Management
Atlanta,
Georgia
|
-$13.7M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.91M |
| 5 |
PC
PointState Capital
New York
|
-$7.51M |
ONCE Hedge Fund Activity: Q4 2016 in Review
119 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Spark Therapeutics, Inc. Common Stock (ONCE) for Q4 2016, worth a combined $1.38B — down 10% from $1.54B a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ONCE and 17 opened new positions — a net loss of 1 holder — while 29 trimmed existing stakes and 53 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $54.5M. The largest seller was Lord, Abbett & Co, cutting an estimated $27.8M.
- 119 institutional investors held Spark Therapeutics, Inc. Common Stock (ONCE) as of Q4 2016, down from 121 in Q3 2016.
- Funds reported $1.38B of Spark Therapeutics, Inc. Common Stock stock for Q4 2016, down 10% quarter-over-quarter.
- 17 funds opened new Spark Therapeutics, Inc. Common Stock positions in Q4 2016 and 18 closed out, a net change of -1 holder.
- The largest Spark Therapeutics, Inc. Common Stock buyer in Q4 2016 was Millennium Management, an estimated $54.5M added.
- The largest Spark Therapeutics, Inc. Common Stock seller in Q4 2016 was Lord, Abbett & Co, an estimated $27.8M sold.
Based on aggregated 13F filings for Q4 2016.